MedTrace Logo

Effect of Pycnogenol® on ADHD

NCT02700685 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2021-04-28

No results posted yet for this study

Summary

This double blind, randomised controlled trial examines the effect of a commercially available nutritional supplement on behaviour of ADHD patients, as well as on their physical and psychiatric co-morbidities, and level of oxidative stress and immune activity, as compared to placebo and standard pharmaceutical treatment for ADHD.

Conditions

  • ADHD

Interventions

DIETARY_SUPPLEMENT

Pycnogenol

Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.

DRUG

Methylphenidate

Standard pharmaceutical treatment for ADHD, slow release.

OTHER

Placebo

Placebo treatment (identical capsules containing excipients only)

Sponsors & Collaborators

  • Nina Hermans

    lead OTHER

Principal Investigators

  • Nina Hermans, PhD · Universiteit Antwerpen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2020-11-20
Completion
2020-11-20

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02700685 on ClinicalTrials.gov